The vaccine and biotechnology company Abera Bioscience strengthens the organization by recruiting the immunologist Emma Ispasanie as translational project scientist. She has experience with OMV technology and vaccine development from preclinical to early clinical phase."We are at a stage where both pace and quality are crucial. Emma has a very strong and relevant profile, and her expertise in immunology, OMVs and clinical preparation is an important addition as we are now running several important projects in parallel," says Maria Alriksson, CEO at Abera Bioscience.